Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 1 July 2007, Vol. 110, No. 1, pp. 171-179.
Prepublished online as a Blood First Edition Paper on March 28, 2007; DOI 10.1182/blood-2007-02-071589.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplemental Figures
Right arrow All Versions of this Article:
blood-2007-02-071589v1
110/1/171    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chen, Z.
Right arrow Articles by Shivdasani, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chen, Z.
Right arrow Articles by Shivdasani, R. A.
Related Collections
Right arrow Hematopoiesis and Stem Cells
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Cytoskeleton
Right arrow Signal Transduction
Right arrowRelated Article in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY

The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway

Zhao Chen1,2, Olaia Naveiras3,4, Alessandra Balduini5, Akiko Mammoto6,7, Mary Anne Conti8, Robert S. Adelstein8, Donald Ingber6,7, George Q. Daley3,4, and Ramesh A. Shivdasani1,2

1 Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; 2 Department of Medicine, Harvard Medical School, Boston, MA; 3 Division of Hematology and Oncology, Children's Hospital, Boston, MA; 4 Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA; 5 Department of Biochemistry, University of Pavia, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy; 6 Vascular Biology Program, Children's Hospital, Boston, MA; 7 Departments of Pathology and Surgery, Harvard Medical School, Boston, MA; and 8 Laboratory of Molecular Cardiology, National Heart, Lung and Blood Institute, Bethesda, MD

The gene implicated in the May-Hegglin anomaly and related macrothrombocytopenias, MYH9, encodes myosin-IIA, a protein that enables morphogenesis in diverse cell types. Defective myosin-IIA complexes are presumed to perturb megakaryocyte (MK) differentiation or generation of proplatelets. We observed that Myh9–/– mouse embryonic stem (ES) cells differentiate into MKs that are fully capable of proplatelet formation (PPF). In contrast, elevation of myosin-IIA activity, by exogenous expression or by mimicking constitutive phosphorylation of its regulatory myosin light chain (MLC), significantly attenuates PPF. This effect occurs only in the presence of myosin-IIA and implies that myosin-IIA influences thrombopoiesis negatively. MLC phosphorylation in MKs is regulated by Rho-associated kinase (ROCK), and consistent with our model, ROCK inhibition enhances PPF. Conversely, expression of AV14, a constitutive form of the ROCK activator Rho, blocks PPF, and this effect is rescued by simultaneous expression of a dominant inhibitory MLC form. Hematopoietic transplantation studies in mice confirm that interference with the putative Rho–ROCK–myosin-IIA pathway selectively decreases the number of circulating platelets. Our studies unveil a key regulatory pathway for platelet biogenesis and hint at Sdf-1/CXCL12 as one possible extracellular mediator. The unexpected mechanism for Myh9-associated thrombocytopenia may lead to new molecular approaches to manipulate thrombopoiesis.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Article in Blood Online:

ROCK and Rho(ll) in bone marrow
Alan T. Nurden
Blood 2007 110: 5-6. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
A. T. Nurden
Thrombus stability on the vessel wall
Blood, July 1, 2008; 112(1): 4 - 5.
[Full Text] [PDF]


Home page
BloodHome page
S. Kunishima, M. Hamaguchi, and H. Saito
Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders
Blood, March 15, 2008; 111(6): 3015 - 3023.
[Abstract] [Full Text] [PDF]


Home page
J. Exp. Med.Home page
N. A. Morin, P. W. Oakes, Y.-M. Hyun, D. Lee, Y. E. Chin, M. R. King, T. A. Springer, M. Shimaoka, J. X. Tang, J. S. Reichner, et al.
Nonmuscle myosin heavy chain IIA mediates integrin LFA-1 de-adhesion during T lymphocyte migration
J. Exp. Med., January 21, 2008; 205(1): 195 - 205.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
A. T. Nurden and P. Nurden
Inherited thrombocytopenias
Haematologica, September 1, 2007; 92(9): 1158 - 1164.
[Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020